01/09/2022
Zdravlje is pleased to announce that as of 1st September 2022, Mr. Tsvetomir Yordanov has joined our senior management team as Group Business Development Director, directly reporting to Kiren Naidoo (CEO). Tsvetomir graduated in International Business and holds a master’s degree in Public Finance from the UNWE (Economics University), Sofia, Bulgaria. […]
18/08/2022
We are pleased to announce that as of 16 August Zdravlje Pharmaceuticals (Bulgaria), a subsidiary of Zdravlje Leskovac, has received a Wholesale Distribution Authorization by the Bulgarian Drug Agency (BDA). “This is an important step for both our Commercial and Contract Development and Manufacturing (CDMO) business lines as we are […]
17/08/2022
The Serbian Agency for Medicines (ALIMS) has approved on 02.08.2022 the Marketing Authorisation for Regkirona (regdanvimab) for Serbia with Zdravlje AD Leskovac as the Marketing Authorisation Holder. Regkirona was one of the first monoclonal antibody medicines thar received The European Medicines Agency (EMA)’s authorisation on 12.11.2021 following a positive opinion […]
08/08/2022
Zdravlje is pleased to announce that as of 1st August 2022, Mr. Milan Markicevic has joined our senior management team as Group Finance Director, directly reporting to Kiren Naidoo (CEO). Milan holds a master’s degree at the Faculty of Economics of the University of Belgrade, strategic financial management module and […]
21/07/2022
As part of the World Exchange Program of Pharmacy and Pharmaceutical Sciences Students (SEP) and the International Pharmacy Students Federation (IPSF) project, which this year marks the 70th anniversary of the first successfully held exchange, Zdravlje, in coordination with the National Association of Pharmacy Students of Serbia, realized a visit […]
17/03/2022
Belgrade, Serbia 17 March 2022 –– Zdravlje A.D. (Zdravlje) announces the signing of a license agreement with the Medicines Patent Pool (MPP) for a generic version of nirmatrelvir, the novel oral COVID-19 antiviral medicine (PF-07321332) developed by Pfizer, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir). This […]
08/03/2022
Zdravlje is pleased to announce that as of 7 March 2022, Radmila Jakovljevic has joined our team as a Supply and Business Development Manager. Radmila will report directly to Dragan Cirkovic, Commercial Director. Radmila graduated from the Faculty of Agriculture at the University in Belgrade, and has a Master degree […]
07/03/2022
Zdravlje is pleased to announce that as of 7 March 2022, Ms. Tamara Vasojevic has joined our senior management team as Group Human Resources Director, directly reporting to Kiren Naidoo (CEO). Tamara graduated from the Faculty of Philosophy in Belgrade, majoring in Adult Education, with additional education and development in […]
28/02/2022
On the occasion of the Rare Disease World Day, 28 February, Zdravlje is sharing the general public information to help raise the awareness and generate the change for the 300 million people worldwide living with a rare disease, their families and carers. What is a rare disease? A disease […]
17/01/2022
Zdravlje is pleased to announce an important expansion of our commercial capabilities in Serbia. As of 10 January, Zdravlje has added five medical representatives who will be working directly with doctors and pharmacists to provide professional support, expertise and information on our high quality product portfolio. Our medical representatives will […]